Among these, RAC1 promotes tumor survival, progression, and therapeutic resistance through a network of anti-apoptotic cell-signaling pathways involving stress responses, cell membrane receptors, active RAC1 variants, reactive oxygen species (ROS) production, and B cell lymphoma/leukemia type 2 (Bcl-2) family activation. Here, BCL2 is linked to neoplasm.